Analyst Maintains Hold on Edwards with Neutral Risk-Reward and Reiterated $85 Price Target Amid Pending TAVR Catalysts
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst William Plovanic maintained a Hold rating on Edwards Lifesciences with an $85 price target. Despite strong quarterly beats in TAVR and TMTT and raised guidance, the recommendation remains neutral due to pending CMS coverage decisions and PROGRESS trial outcomes. Concerns include cautious management outlook for H2, tougher comparisons, FX margin pressure, and valuation already pricing in growth.
Canaccord Genuity analyst William Plovanic maintained a Hold rating on Edwards Lifesciences yesterday and set a price target of $85.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
William Plovanic has given his Hold rating due to a combination of factors tied to Edwards’ current performance and its risk‑reward profile. The company delivered a strong quarterly beat in both TAVR and TMTT, and management raised full‑year revenue guidance, but the increase largely mirrors the recent upside rather than signaling a fundamentally higher growth trajectory.
At the same time, key catalysts for the core TAVR business, including the final CMS coverage decision and the PROGRESS trial outcome, are still pending and could materially influence the long‑term outlook. Management’s cautious stance on the second half of the year, tougher TAVR comparisons, FX‑driven margin pressure, and a valuation that already discounts much of the expected growth collectively support maintaining a neutral, Hold recommendation and an $85 price target.
According to TipRanks, Plovanic is a 2-star analyst with an average return of 0.0% and a 40.88% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as TransMedics Group, Atricure, and Artivion.